Effects of flurbiprofen and tiaprofenic acid on oxidative stress markers in osteoarthritis: a prospective, randomized, open-label, active- and placebo-controlled trial

dc.authorid0000-0001-6873-5730en_US
dc.authorid0000-0002-1347-8498en_US
dc.authorid0000-0002-3300-2286
dc.authorid0000-0002-8929-6973
dc.contributor.authorTüzün, Şansın
dc.contributor.authorUzun, Hafize
dc.contributor.authorAydın, Seval
dc.contributor.authorDinç, Ahmet
dc.contributor.authorSipahi, Sevtap
dc.contributor.authorTopçuoğlu, Mehmet Ata
dc.contributor.authorYücel, Rıfat
dc.date.accessioned2021-06-23T19:18:19Z
dc.date.available2021-06-23T19:18:19Z
dc.date.issued2005
dc.departmentBAİBÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: The relationship between oxidative stress and osteoarthritis (OA) has been widely investigated. Serum malondialdehyde (MDA), nitric oxide (NO), and Cu/Zn superoxide dismutase (SOD) levels are useful markers of oxidative stress. Because of the importance of oxidative stress markers in the pathogenesis of OA, treatment might involve modification of these markers to control oxidative stress. Objective: The aim of this study was to compare the effects of 2 conventional NSAIDs on markers of oxidative stress in patients with OA of the knee. Methods: This 3-week, prospective, randomized, open-label, active- and placebo-controlled study was conducted at the Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey Adult patients with clinically and radiographically diagnosed moderate OA of the knee who were previously untreated were enrolled. Patients were randomly assigned to 1 of 3 treatment groups: flurbiprofen 100 mg PO (tablets) BID, tiaprofenic acid 300 mg PO (tablets) BID, or placebo tablets BID. Patients were evaluated using clinical assessment and laboratory testing before treatment (week 0; baseline) and at the end of week 3. The primary end points were the differences in serum MDA, NO, and SOD levels versus placebo. Clinical parameters-pain at rest and on motion-were evaluated using a 10-cm visual analog scale (0 = no pain to 10 = worst pain imaginable). The duration (in minutes) of morning stiffness was recorded by patients, using patient diaries. The differences between treatment groups were assessed using multivariate analysis. Results: Thirty-nine patients (20 women, 19 men; mean [SD] age, 59.0 [11.3] years) were included in the study Mean serum MDA and NO levels were significantly decreased at 3 weeks compared with baseline in the 2 active-treatment groups (all, P < 0.001); these values remained statistically similar to baseline in the placebo group. Serum SOD levels were increased significantly from baseline in the 2 active-treatment groups (both, P < 0.00 1), but not in the placebo group. No significant differences in serum MDA and NO levels were found between the group receiving flurbiprofen and that receiving tiaprofenic acid. Serum SOD levels were significantly higher in the flurbiprofen group compared with the tiaprofenic acid and placebo groups (both, P < 0.0 1). The mean (SD) score for pain at rest was significantly lower at 3 weeks compared with baseline with flurbiprofen and tiaprofenic acid (both, P < 0.00 1), but not with placebo. The mean score for pain on motion was significantly reduced from baseline values only with tiaprofenic acid (P < 0.001). The duration of morning stiffness was significantly shorter at 3 weeks compared with baseline in all 3 study groups (all, P < 0.001). The mean scores for pain on motion and duration of morning stiffness were significantly reduced with tiaprofenic acid compared with placebo (both, P < 0.05). The study had some limitations (ie, small sample size, no blinding, the short duration of the study, and the weak correlation between serum and synovial fluid levels of NO). Conclusions: In this comparison of the effects of 3 weeks of treatment with flurbiprofen 100 mg BID and tiaprofenic acid 300 mg BID in patients with knee OA, both treatments effectively reduced serum MDA and NO levels compared with placebo. Only tiaprofenic acid significantly improved pain at rest and on motion and duration of morning stiffness compared with placebo.en_US
dc.identifier.doi10.1016/j.curtheres.2005.08.002
dc.identifier.endpage344en_US
dc.identifier.issn0011-393X
dc.identifier.issn1879-0313
dc.identifier.issue4en_US
dc.identifier.pmid24672133en_US
dc.identifier.scopus2-s2.0-26444558043en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage335en_US
dc.identifier.urihttps://doi.org/10.1016/j.curtheres.2005.08.002
dc.identifier.urihttps://hdl.handle.net/20.500.12491/5700
dc.identifier.volume66en_US
dc.identifier.wosWOS:000231920000007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorTopçuoğlu, Mehmet Ata
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofCurrent Therapeutic Research-Clinical And Experimentalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectOsteoarthritisen_US
dc.subjectMalondialdehydeen_US
dc.subjectNitric Oxideen_US
dc.subjectSuperoxide Dismutaseen_US
dc.subjectNSAIDsen_US
dc.titleEffects of flurbiprofen and tiaprofenic acid on oxidative stress markers in osteoarthritis: a prospective, randomized, open-label, active- and placebo-controlled trialen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
sansin-tuzun.pdf
Boyut:
593.53 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/ Full text